EU/3/16/1616:

Diclofenamide

Overview

On 17 February 2016, orphan designation (EU/3/16/1616) was granted by the European Commission to Professor Michael Hanna, United Kingdom, for diclofenamide for the treatment of periodic paralysis.

The sponsorship was transferred to  Giampietro Schiavo, Italy in April 2021.

Key facts

Active substance
Diclofenamide
Intented use
Treatment of periodic paralysis
Date of designation
17/02/2016
Orphan designation status
Positive
EU designation number
EU/3/16/1616

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Giampietro Schiavo
Via Luigi Cadorna 16 
35031 Abano Terme (PD) 
Italy
Email: cnmd.contact@ucl.ac.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating